Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This clinical research will evaluate the diagnostic potential of fluorescein as visualized
through an operating microscope relative to 1) contrast enhancement on co-registered
preoperative MR scans, 2) intraoperative ALA-induced PpIX fluorescence and 3) gold-standard
histology obtained from biopsy sampling during the procedure.
Subjects will include those people with operable brain tumor with first-time presumed
pre-surgical diagnosis of high-grade glioma or low-grade glioma.
Phase:
Phase 2
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center David W. Roberts
Collaborators:
Carl Zeiss Meditec, Inc. National Institute of Neurological Disorders and Stroke (NINDS)